Skip to main content
padlock icon - secure page this page is secure

Clinical utility of (99mTc)‐TRODAT‐1 scans to differentiate Parkinsonian syndromes: case studies and commentary

Buy Article:

$52.00 + tax (Refund Policy)

The differential diagnosis of Parkinsonian syndromes is challenging, especially in the elderly as they often have complex presentations. Nuclear imaging modalities can increase diagnostic accuracy. Single‐photon emission tomography (SPECT) using the ligand (99mTc)‐TRODAT‐1 is used overseas but is yet to be approved in Australia. Three pilot cases of clinically unclear Parkinsonian syndromes from the Royal North Shore Hospital Aged Care Department who underwent (99mTc)‐TRODAT‐1 scans are described. From experience overseas, the (99mTc)‐TRODAT‐1 scan has clinical utility in the differential diagnosis of Parkinsonian syndromes. (99mTc)‐TRODAT‐1 has a lower cost and greater availability than other ligands. Our initial scan findings are largely consistent with the clinical picture, but low specific binding can affect scan interpretation. (99mTc)‐TRODAT‐1 is a potential tool in the differential diagnosis of Parkinsonian syndromes. Further experience regarding its effect on patient outcomes and cost effectiveness is required before routine clinical use can be recommended.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Australia; Parkinsonian disorders; TRODAT; single‐photon emission computed tomography

Document Type: Research Article

Publication date: September 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more